162 related articles for article (PubMed ID: 20140460)
21. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders presented as interstitial pneumonia; successful recovery with rituximab.
Kunitomi A; Arima N; Ishikawa T
Haematologica; 2007 Apr; 92(4):e49-52. PubMed ID: 17562592
[TBL] [Abstract][Full Text] [Related]
22. Post-Transplant Lymphoproliferative Diseases in Pediatric Kidney Allograft Recipients with Epstein-Barr Virus Viremia.
Hyun H; Park E; Cho M; Min SI; Ha J; Kang HJ; Shin HY; Ha IS; Cheong HI; Ahn YH; Kang HG
J Korean Med Sci; 2019 Aug; 34(30):e203. PubMed ID: 31373185
[TBL] [Abstract][Full Text] [Related]
23. Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab.
Muzaffar M; Taj A; Ratnam S
Am J Ther; 2010; 17(6):e230-3. PubMed ID: 19918163
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
[TBL] [Abstract][Full Text] [Related]
25. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
Zilz ND; Olson LJ; McGregor CG
J Heart Lung Transplant; 2001 Jul; 20(7):770-2. PubMed ID: 11448808
[TBL] [Abstract][Full Text] [Related]
26. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
27. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
Yedibela S; Reck T; Niedobitek G; Gramatzki M; Repp R; Hohenberger W; Ott R
Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216
[TBL] [Abstract][Full Text] [Related]
28. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.
Yang J; Tao Q; Flinn IW; Murray PG; Post LE; Ma H; Piantadosi S; Caligiuri MA; Ambinder RF
Blood; 2000 Dec; 96(13):4055-63. PubMed ID: 11110673
[TBL] [Abstract][Full Text] [Related]
29. Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.
Ferguson NN; Thomas CP; Hohl RJ; Syrbu SI; Stone MS; Wanat KA
Am J Dermatopathol; 2015 Oct; 37(10):790-4. PubMed ID: 25747810
[TBL] [Abstract][Full Text] [Related]
30. Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement.
Hänel M; Fiedler F; Thorns C
Onkologie; 2001 Oct; 24(5):491-4. PubMed ID: 11694778
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation.
Herman J; Vandenberghe P; van den Heuvel I; Van Cleemput J; Winnepenninckx V; Van Damme-Lombaerts R
J Heart Lung Transplant; 2002 Dec; 21(12):1304-9. PubMed ID: 12490276
[TBL] [Abstract][Full Text] [Related]
32. Acute cellular rejection and Epstein-Barr virus-related post-transplant lymphoproliferative disorder in a pediatric lung transplant with low viral load.
Calabrese F; Loy M; Lunardi F; Marino D; Aversa SM; Rea F
Transpl Infect Dis; 2010 Aug; 12(4):342-6. PubMed ID: 20030794
[TBL] [Abstract][Full Text] [Related]
33. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
Czyzewski K; Styczynski J; Krenska A; Debski R; Zajac-Spychala O; Wachowiak J; Wysocki M
Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
Ellis D; Jaffe R; Green M; Janosky JJ; Lombardozzi-Lane S; Shapiro R; Scantlebury V; Vivas C; Jordan ML
Transplantation; 1999 Oct; 68(7):997-1003. PubMed ID: 10532541
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapy.
Said-Conti V; Amrolia PJ; Gaze MN; Stoneham S; Sebire N; Shroff R; Marks SD
Pediatr Nephrol; 2013 Oct; 28(10):2053-6. PubMed ID: 23743853
[TBL] [Abstract][Full Text] [Related]
37. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.
Jagadeesh D; Woda BA; Draper J; Evens AM
Curr Treat Options Oncol; 2012 Mar; 13(1):122-36. PubMed ID: 22241590
[TBL] [Abstract][Full Text] [Related]
38. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
[TBL] [Abstract][Full Text] [Related]
39. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL
Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399
[TBL] [Abstract][Full Text] [Related]
40. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]